Related Experiment Video

Updated: Sep 21, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

[Guillain-Barré syndrome: epidemiological, clinical and therapeutic insight]

J C Raphaël1, T Sharshar

  • 1Service de Réanimation Médicale, Hôpital Raymond-Poincaré, 92380 Garches.

Annales De Medecine Interne
|July 18, 2000
PubMed

Insights

Guillain-Barré syndrome treatment guidelines recommend plasma exchange (PE) or intravenous immunoglobulin (IVIg) for severe cases. Corticosteroids are ineffective for this neurological disorder.

Area of Science:

  • Neurology
  • Immunology

Context:

  • Guillain-Barré syndrome (GBS) is a rare autoimmune disorder affecting the peripheral nervous system.
  • The incidence of GBS is approximately 1.5 per 100,000 individuals annually.
  • Severe neurological sequelae affect 10% of patients one year post-onset, necessitating specialized hospital care.

Purpose:

  • To outline current treatment recommendations for Guillain-Barré syndrome based on clinical trial evidence.
  • To specify indications for plasma exchange (PE) and high-dose intravenous immunoglobulin (IVIg) in different GBS severity forms.
  • To highlight the ineffectiveness of corticosteroids in GBS treatment.

Summary:

  • Plasma exchange (PE) is the first proven treatment for GBS, with specific protocols based on patient mobility and ventilation status.
  • Four PE sessions are recommended for intermediate or severe GBS forms.
  • High-dose IVIg (0.4 g/kg/day for 5 days) demonstrates equivalent efficacy to PE in intermediate and severe GBS.
  • Ongoing studies aim to optimize IVIg dosage and PE frequency for various GBS severity levels.

Impact:

  • Established evidence-based guidelines for GBS management, improving patient outcomes.
  • Identified ineffective treatments (corticosteroids), preventing their use and associated side effects.
  • Provided a foundation for further research into optimal GBS therapies, including dosage and treatment duration.

More Related Videos

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo10:50

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo

Published on: March 26, 2019

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...